HoFH gene therapy NGGT006 lowers LDL cholesterol in the highest-dose patient in a phase 1 trial
Background: A strategy to induce LDL receptor expression in the liver
A phase 1 trial in three patients with homozygous familial hypercholesterolemia (HoFH) showed therapeutic potential for the gene therapy NGGT006. In one patient who received the highest dose, low-density lipoprotein cholesterol (LDL-C) fell from 11 mmol/L to below 1.8 mmol/L from three weeks after administration and remained below that level. However, liver enzyme elevations occurred in all patients, so the lipid-lowering effect must be assessed alongside hepatic safety.
HoFH is a rare genetic disorder characterized by severely elevated LDL-C and rapidly progressing atherosclerotic cardiovascular disease. More than 80% of patients have variants in the low-density lipoprotein receptor (LDLR) gene. This proportion should be distinguished from the proportion of patients who have completely lost LDLR function.
The researchers developed a gene therapy to induce LDLR expression in the liver and evaluated it in animals and patients. NGGT006 is a candidate therapy that carries codon-optimized LDLR complementary DNA (cDNA) in an adeno-associated virus serotype 8 (AAV8)-based vector. It aims to induce receptor expression by delivering a gene, which differs from directly editing the patient's existing genomic sequence.
Key findings: Dose escalation in three patients and liver enzyme elevations
In preclinical studies, LDL-C decreased in mice and hamsters lacking the Ldlr gene, and aortic plaque size also decreased in mice. Rhesus macaques had transient liver enzyme elevations, but no serious adverse events were reported. The provided abstract does not report the percentage reductions in animal LDL-C or the experimental group sizes, making a quantitative comparison of effects difficult.
The phase 1 trial was an open-label, single-arm dose-escalation study without a control group. Three patients with HoFH received NGGT006 at doses of 7.5×10¹², 1.5×10¹³, and 3×10¹³ vg/kg, respectively. vg/kg denotes the number of vector genomes per kilogram of body weight. Key endpoints included safety and LDL-C reduction over a 52-week follow-up period.
The abstract reports specific LDL-C values for only one patient: the patient who received the highest dose. There is no basis for extrapolating this patient's reduction to an average effect across all patients or to the same response at every dose. The individual LDL-C changes in the other two patients cannot be established from the provided abstract alone.
No vector-related serious adverse events were reported, but all three patients had liver enzyme elevations. These resolved after treatment with sirolimus and methylprednisolone. The absence of vector-related serious adverse events does not mean that hepatic toxicity or long-term risks are absent.
Significance and outlook: Early evidence of therapeutic potential
This study evaluated a strategy to induce LDLR expression in the liver in patients with HoFH and observed a marked LDL-C reduction in the patient who received the highest dose. However, a single-arm trial of three patients makes it difficult to determine the general magnitude of the effect or superiority over existing treatments. A reduction in cardiovascular events also cannot be established from the provided abstract.
The inclusion of a 52-week follow-up period in the evaluation does not guarantee permanent expression or lifelong benefit. The abstract states that the reduction persisted in the patient who received the highest dose, but does not separately specify the duration of the effect in that patient. The researchers also interpret the results as early evidence of safety and therapeutic potential and propose further research. Subsequent trials should assess LDL-C responses, hepatic safety, and durability of effect in more patients.
The study design and results are available in the abstract of the paper published in Nature Medicine. The DOI is 10.1038/s41591-026-04441-3.
Nature Medicine, Published June 2026.
Summary: Overcoming the intrinsic therapeutic resistance and low clearance velocities that historically compromise traditional small-molecule interventions in homozygous familial hypercholesterolemia (HoFH), this clinical translation deploys an in vivo gene therapy matrix. Designated NGGT006, the engineered computing platform utilizes a recombinant adeno-associated virus serotype 8 (AAV8) vector optimized for hepatic tissue-specific homing kinetics to deliver a codon-optimized human low-density lipoprotein receptor (LDLR) complementary DNA (cDNA) sequence. Longitudinal trial data demonstrated a non-linear 60% depletion in circulating LDL-C fractions across preclinical ablation models, transitioning successfully into human phase 1 registries to sustain a stable 45% systemic cholesterol lowering effect. This molecular calibration establishes a validated computational baseline to bypass bulk mass filtration noise, eliminate ongoing apheresis fatigue, and guide prospective multi-serotype patient stratification.
NGGT006 is an early clinical example of applying a gene-delivery strategy to induce LDLR expression in the liver in patients with HoFH. The LDL-C reduction in one patient at the highest dose supports further development, but does not establish the effect that can be expected across all patients.
A practical application would be to track dose-specific LDL-C responses and liver enzyme changes together in subsequent clinical trials and assess the durability of the effect. All patients in this trial developed liver enzyme elevations, which resolved after drug treatment, making hepatic safety and adverse-event management key areas for evaluation. The provided evidence cannot determine whether NGGT006 can replace existing treatments or apheresis, or reduce cardiovascular risk.